- Home
- PHAR vs STAA Comparison
PHAR vs STAA Comparison
Compare PHAR & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- STAA
- Stock Information
- Founded
- PHAR 1988
- STAA 1982
- Country
- PHAR Netherlands
- STAA United States
- Employees
- PHAR N/A
- STAA N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- STAA Ophthalmic Goods
- Sector
- PHAR Health Care
- STAA Health Care
- Exchange
- PHAR Nasdaq
- STAA Nasdaq
- Market Cap
- PHAR 731.1M
- STAA 850.9M
- IPO Year
- PHAR N/A
- STAA N/A
- Fundamental
- Price
- PHAR $10.00
- STAA $17.17
- Analyst Decision
- PHAR Strong Buy
- STAA Hold
- Analyst Count
- PHAR 3
- STAA 8
- Target Price
- PHAR $30.00
- STAA $27.17
- AVG Volume (30 Days)
- PHAR 3.6K
- STAA 758.1K
- Earning Date
- PHAR 07-31-2025
- STAA 08-06-2025
- Dividend Yield
- PHAR N/A
- STAA N/A
- EPS Growth
- PHAR N/A
- STAA N/A
- EPS
- PHAR N/A
- STAA N/A
- Revenue
- PHAR $320,708,000.00
- STAA $279,134,000.00
- Revenue This Year
- PHAR $13.31
- STAA N/A
- Revenue Next Year
- PHAR $7.68
- STAA $27.83
- P/E Ratio
- PHAR N/A
- STAA N/A
- Revenue Growth
- PHAR 24.13
- STAA N/A
- 52 Week Low
- PHAR $6.65
- STAA $13.50
- 52 Week High
- PHAR $12.61
- STAA $49.86
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- STAA 49.02
- Support Level
- PHAR $9.99
- STAA $16.52
- Resistance Level
- PHAR $10.59
- STAA $18.00
- Average True Range (ATR)
- PHAR 0.35
- STAA 0.69
- MACD
- PHAR -0.14
- STAA 0.09
- Stochastic Oscillator
- PHAR 7.45
- STAA 53.85
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.